January
4+ new clinical trials being discussed for the near future
February
First patient completed the Verapamil study
May
MELD-ATG trial open for the 5-11 years old
June
• Last patient completing treatment in IMPACT
• INNODIA business plan for sustainability
• First two children (<12yrs) randomised in MELD-ATG
August
• Last participants included in Ver-A-T1D
• Final visit of last participant Ver-A-T1D
September
Target end of recruitment in IMPACT
December 15th
Iscalimab trial closed to new enrollment
